Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
New Advances in Gastroesophageal Reflux Disease
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

New Advances in Gastroesophageal Reflux Disease

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 19255

Special Issue Editor

Prof. Dr. Hidekazu Suzuki

E-Mail Website
Guest Editor
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan
Interests: gastroesophageal reflux disease; esophageal cancer; eosinophilic esophagitis; chronic gastritis; gastric cancer; peptic ulcer; gastric MALT lymphoma; colorectal cancer; functional dyspepsia; IBS; IBD
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Gastroesophageal reflux disease (GERD) is the most prevalent gastrointestinal tract disease in the world and has recently been increasing in incidence not only in Europe and the United States but also in Asia. These are organic diseases that show reflux of gastric contents to the esophagus, but there is erosive reflux esophagitis that shows erosion in the lower esophageal mucosa and non-erosive gastroesophageal reflux disease (NERD) that does not show erosion. Furthermore, recently, although there is no reflux of gastric contents to the esophagus, it has become important to differentiate it from functional esophageal diseases such as functional heartburn and reflux hypersensitivity that show heartburn and acid reflux symptoms as in GERD. In recent years, with the progress of high-resolution manometry and 24 h pH-monitoring devices, it has become possible to distinguish organic esophageal motility disorders such as esophageal achalasia, Jackhammer’s disease, and diffuse esophageal spasm. In addition, it is important to distinguish eosinophilic esophagitis, whose number of patients is increasing in recent years. The mainstream of treatment is acid secretion inhibitors, but recently, P-CAB with a different action point from PPI has appeared, and it has been shown to have epoch-making effects. Unlike conventional PPI, it has an early and stable effect of increasing gastric pH and has become a drug that can almost reach the cure even in refractory erosive esophagitis. Furthermore, recent advances in prokinetics have enabled long-term control of lesions and symptoms when used in combination with PPI or P-CAB. This may include herbal medicine. On the other hand, the development of a method for inhibiting the gastroesophageal reflux mechanism endoscopically or surgically, which is not drug therapy, is also rapidly progressing. In this Special Issue, I would like to present the latest progress on GERD as a cutting-edge feature.

Prof. Dr. Hidekazu Suzuki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • high resolution manometry
  • 24 h pH monitoring
  • ARMS or ARMA
  • surgery
  • PCAB
  • PPI
  • prokinetics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1794 KiB  
Article
Additional Mosapride to Proton Pump Inhibitor for Gastroesophageal Reflux Disease: A Meta-Analysis
by Toshihiro Nishizawa, Kiyoto Mori, Shuntaro Yoshida, Hirotoshi Ebinuma, Osamu Toyoshima and Hidekazu Suzuki
J. Clin. Med. 2020, 9(9), 2705; https://doi.org/10.3390/jcm9092705 - 21 Aug 2020
Cited by 6 | Viewed by 3441
Abstract
Background and Aim: In gastroesophageal reflux disease (GERD), the additive effect of mosapride to a proton pump inhibitor (PPI) is still controversial. This meta-analysis integrated randomized controlled trials (RCTs) in which mosapride combined with a PPI was compared with a PPI alone in [...] Read more.
Background and Aim: In gastroesophageal reflux disease (GERD), the additive effect of mosapride to a proton pump inhibitor (PPI) is still controversial. This meta-analysis integrated randomized controlled trials (RCTs) in which mosapride combined with a PPI was compared with a PPI alone in GERD treatment. Methods: RCTs were systematically searched with the PubMed, Cochrane library, Web of Science, and the Igaku-Chuo-Zasshi database. We combined the data from the RCTs with a random effects model, calculated the standardized mean difference (SMD) and pooled the risk difference (RD) with 95% confidence intervals (CIs). Results: We included nine RCTs in the present meta-analysis. In the mosapride combined with PPI group, the improvement of the symptom score was significantly greater than that in the PPI alone group without significant heterogeneity (SMD: −0.28, 95% CI: −0.45 to −0.12, p = 0.0007). In the mosapride combined with PPI group, the symptom score after treatment was significantly lower than that in the PPI alone group (SMD: −0.24, 95% CI: −0.42 to −0.06, p = 0.007). Conclusions: Mosapride combined with a PPI significantly improved the reflux symptom score compared with that of PPI alone. Full article
(This article belongs to the Special Issue New Advances in Gastroesophageal Reflux Disease)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 1363 KiB  
Review
Extracellular miRNAs for the Management of Barrett’s Esophagus and Esophageal Adenocarcinoma: A Systematic Review
by Kazumi Inokuchi, Takahiro Ochiya and Juntaro Matsuzaki
J. Clin. Med. 2021, 10(1), 117; https://doi.org/10.3390/jcm10010117 - 31 Dec 2020
Cited by 5 | Viewed by 3271
Abstract
Esophageal adenocarcinoma (EAC), the major histologic type of esophageal cancer (EC) in Western countries, is a disease with a poor prognosis, primarily due to usual diagnosis at an advanced stage. The prevalence of EAC has increased in recent years, both in Western countries [...] Read more.
Esophageal adenocarcinoma (EAC), the major histologic type of esophageal cancer (EC) in Western countries, is a disease with a poor prognosis, primarily due to usual diagnosis at an advanced stage. The prevalence of EAC has increased in recent years, both in Western countries and in Asia. Barrett’s esophagus (BE) is a precursor lesion of EAC. Therefore, early detection and proper management of BE and EAC is important to improve prognosis. Here, we systematically summarize current knowledge about the potential utility of extracellular microRNAs (miRNAs), which are thought to be non-invasive biomarkers for many diseases, for these purposes. A search of the PubMed and Embase databases identified 22 papers about extracellular miRNAs that have potential utility for management of EAC. Among them, 19 were EAC-related and ten were BE-related; some of these dealt with both conditions. The articles included studies reporting diagnosis, prognosis, and treatment responses. Multiple papers report dysregulation of miR-194-5p in BE and miR-21-5p, -25-3p, and -93-5p in EAC. Although it will take time to utilize these miRNAs in clinical practice, they are likely to be useful non-invasive markers in the future. Full article
(This article belongs to the Special Issue New Advances in Gastroesophageal Reflux Disease)
►▼ Show Figures

Figure 1

14 pages, 2437 KiB  
Review
Belching in Gastroesophageal Reflux Disease: Literature Review
by Akinari Sawada, Yasuhiro Fujiwara and Daniel Sifrim
J. Clin. Med. 2020, 9(10), 3360; https://doi.org/10.3390/jcm9103360 - 20 Oct 2020
Cited by 12 | Viewed by 9706
Abstract
Belching is a common phenomenon. However, it becomes bothersome if excessive. Impedance–pH monitoring can classify the belching into two types: gastric belching and supragastric belching (SGB). The former is a physiological mechanism to vent swallowed air from the stomach, whereas the latter is [...] Read more.
Belching is a common phenomenon. However, it becomes bothersome if excessive. Impedance–pH monitoring can classify the belching into two types: gastric belching and supragastric belching (SGB). The former is a physiological mechanism to vent swallowed air from the stomach, whereas the latter is a behavioral disorder. Gastroesophageal reflux disease (GERD) is the most relevant condition in both types of belching. Recent findings have raised awareness that excessive SGB possibly sheds light on the pathogenesis of a part of proton pump inhibitor (PPI) refractoriness in GERD. SGB could cause typical reflux symptoms such as heartburn, regurgitation or chest pain in two ways: SGB-induced gastroesophageal reflux or SGB-induced esophageal distension. In PPI-refractory GERD, it is important to detect hidden SGB as a cause of reflux symptoms since SGB requires psychological treatment instead of high dose PPIs or pain modulators. In the case of PPI-refractory GERD with excessive SGB, recent studies imply that the combination of a psychological approach and conventional treatment can improve treatment outcome. Full article
(This article belongs to the Special Issue New Advances in Gastroesophageal Reflux Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop